Delving into the Latest Updates on STEMVAC(EpiThany) with Synapse

Overview

Basic Info

Drug Type

DNA vaccine, Therapeutic vaccine

Synonyms

CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine(EpiThany, Inc.)

Target

CDH3 x ENG x MDM2 x SOX2 x Yb-1

Action

inhibitors

Mechanism

CDH3 inhibitors(Cadherin 3 inhibitors), ENG inhibitors(endoglin inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors)

+ [2]

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication

Breast Cancer

Inactive Indication-

Originator Organization

EpiThany, Inc.

Active Organization

EpiThany, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer. STEMVAC targets specific immunogenic proteins that help lung cancer cells to grow. STEMVAC is made up of deoxyribonucleic acid (DNA), which is a natural substance in every living organism. DNA acts like a blueprint that tells all the cells in your body how to function. The DNA used in this study contains instructions for your body to produce parts of the 5 proteins the investigators identified (CDH3, CD105, YB-1, MDM2 and SOX2). STEMVAC is given with granulocyte-macrophage colony stimulating factor (GM-CSF) which is being used as an adjuvant to help create a stronger immune response. Giving STEMVAC with GM-CSF to patients while on maintenance therapy for non-small cell lung cancer (NSCLC) may help activate certain immune cells to recognize and kill lung cancer cells.

Start Date24 Mar 2023

Sponsor / Collaborator

University of Washington

[+1]

NCT05455658

/ RecruitingPhase 2IIT

A Phase II Trial of The Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDC25B, CD105) in Participants With Early Stage Triple Negative Breast Cancer

This phase II trial studies the effect of DNA plasmid based vaccine (STEMVAC) in treating patients with patients with stage IB-III triple negative breast cancer. STEMVAC may wake up the immune system in patients who have had a diagnosis of triple negative breast cancer and have been treated. STEMVAC targets proteins that are expressed on breast cancer cells and works by boosting the immune system to recognize and destroy the invader cancer cell proteins that are causing the disease. The purpose of this trial is to test the immune system's response to STEMVAC.

Start Date17 Nov 2022

Sponsor / Collaborator

University of Washington

[+2]

NCT02157051

/ Active, not recruitingPhase 1IIT

A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients

This phase I trial studies the side effects and best dose of multiantigen deoxyribonucleic acid (DNA) plasmid-based vaccine in treating patients with human epidermal growth factor receptor 2 (HER2)-negative stage III-IV breast cancer. Multiantigen DNA plasmid-based vaccine may target immunogenic proteins expressed in breast cancer stem cells which are the component of breast cancer that is resistant to chemotherapy and has the ability to spread. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells.

Start Date01 Jun 2015

Sponsor / Collaborator

University of Washington

[+2]

100 Clinical Results associated with STEMVAC(EpiThany)

Login to view more data

100 Translational Medicine associated with STEMVAC(EpiThany)

Login to view more data

100 Patents (Medical) associated with STEMVAC(EpiThany)

Login to view more data

100 Deals associated with STEMVAC(EpiThany)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Phase 1	United States	EpiThany, Inc.	18 Aug 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02157051 (SITC2022) Manual	Phase 1	Advanced breast cancer	-	STEMVAC 150mcg/300mcg/600mcg	(zdpvexmbwt) = pngwcbguxs dbaabqmqkz (mjsmrnulyi ) View more	Positive	01 Nov 2022
ERS2011	Not Applicable	Pulmonary Disease, Chronic Obstructive	42	EP-101 12.5 μg	pjtexjljnj(zxsyzhtfgs) = gspogblmsr tswgxuqzqf (fgjeknezbf ) View more	Positive	01 Sep 2011
ERS2011	Not Applicable	Pulmonary Disease, Chronic Obstructive	42	EP-101 50 μg	pjtexjljnj(zxsyzhtfgs) = rtlrprlqyo tswgxuqzqf (fgjeknezbf ) View more	Positive	01 Sep 2011